Начало › Рак на белия дроб с недребноклетъчен тип › Охайо › Columbus
Клинични проучвания за Рак на белия дроб с недребноклетъчен тип в Columbus, OH
57 проучвания за Рак на белия дроб с недребноклетъчен тип търсят участници в обекти в и около Columbus (в радиус от около 30 мили). Отворете проучването, за да видите кой може да участва и как да се свържете с екипа.
Официален текст на проучването (английски)
Търсите участници за проучване? Представяме го в началото на тази страница — $99 за 30 дни →
Study to Evaluate Adverse Events and Efficacy of Intravenous (IV) Telisotuzumab Adizutecan in Combination With a PD-1 Immune Checkpoint Inhibitor in Adult Participants With Advanced or Metastatic Non-Squamous NSCLC With No Prior Treatment for Advanced Disease, and No Actionable Genomic Alterations
Набиране на участнициФаза 1/2
- The Mark H Zangmeister Center /ID# 272502, Columbus
Testing the Addition of a Type of Drug Called Immunotherapy to the Usual Chemotherapy Treatment for Non-small Cell Lung Cancer, an ALCHEMIST Treatment Trial (Chemo-IO [ACCIO])
Набиране на участнициФаза 3
- Mount Carmel East Hospital, Columbus
- The Mark H Zangmeister Center, Columbus
- Mount Carmel Health Center West, Columbus
- и още 3
Phase 1 Study of OP-3136 in Advanced or Metastatic Solid Tumors
Набиране на участнициФаза 1
- The Ohio State University, Columbus
A Study of Targeted Post-Surgery Radiation Therapy for Non-Small Cell Lung Cancer With Remaining Lymph Node Cancer After Treatment
Набиране на участнициФаза 2
- Ohio State University Comprehensive Cancer Center, Columbus
A Study To Assess the Safety, Tolerability, and Efficacy of Imzokitug in Combination With Pumitamig and Platinum-Doublet Chemotherapy (PDCT) Versus Pumitamig and PDCT as First-line Treatment for Participants With Locally Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC)
Набиране на участнициФаза 2
- Local Institution - 0176, Columbus
Immunotherapy After Surgery for People Who Have No Remaining Cancer Cells After Standard Treatment for Early-Stage Non-Small Cell Lung Cancer, INSIGHT Trial
Набиране на участнициФаза 3
- Ohio State University Comprehensive Cancer Center, Columbus
A First in Human Study of ALX2004 With Advanced or Metastatic Selected Solid Tumors
Набиране на участнициФаза 1
- ALX Center 10, Columbus
Neladalkib (NVL-655) for TKI-naive Patients With Advanced ALK-Positive NSCLC
Набиране на участнициФаза 3
- The Ohio State University, Columbus
Solid Tumor Analysis for HLA Loss of Heterozygosity (LOH) and Apheresis for CAR T- Cell Manufacturing
Набиране на участнициНаблюдателно проучване
- The Ohio State University Comprehensive Cancer Center, Columbus
Testing Osimertinib as a Treatment for Lung Cancers With an EGFR Exon 20 Change
Набиране на участнициФаза 2
- Ohio State University Comprehensive Cancer Center, Columbus
Study of Olomorasib (LY3537982) in Combination With Standard of Care in Participants With Resected or Unresectable KRAS G12C-mutant Non-Small Cell Lung Cancer
Набиране на участнициФаза 3
- The James Cancer Hospital and Solove Research Institute at The Ohio State University Comprehensive Cancer -T, Columbus
- OhioHealth Riverside Methodist Hospital, Columbus
A Study to Evaluate the Safety, Tolerability, Drug Levels, and Preliminary Efficacy of BMS-986507 Combinations in Adult Participants With Advanced Solid Tumors
Набиране на участнициФаза 1/2
- Local Institution - 0102, Columbus
Study of Izalontamab Brengitecan (BMS-986507) Versus Platinum-Pemetrexed for EGFR-mutated Non-small Cell Lung Cancer After Failure of EGFR TKI Therapy (IZABRIGHT-Lung01)
Набиране на участнициФаза 2/3
- The James Cancer Hospital and Solove Research Institute at The Ohio State University Comprehensive C, Columbus
Personalized Cancer Vaccine (PCV) Strategy in Patients With Solid Tumors and Molecular Residual Disease
Набиране на участнициФаза 1
- Ohio State University, Columbus
Clinical Study of Ivonescimab for First-line Treatment of Metastatic NSCLC Patients With High PD-L1
Набиране на участнициФаза 3
- Clinical Study Sites, Columbus
- Clinical Study Site, Columbus
Phase 2 Trial of Adagrasib Monotherapy and in Combination With Pembrolizumab and a Phase 3 Trial of Adagrasib in Combination in Patients With a KRAS G12C Mutation KRYSTAL-7
Набиране на участнициФаза 2/3
- Mark H. Zangmeister Cancer Center, Columbus
Osimertinib and Tegavivint as First-Line Therapy for the Treatment of Metastatic EGFR-Mutant Non-small Cell Lung Cancer
Набиране на участнициФаза 1
- Ohio State University Comprehensive Cancer Center, Columbus
FiH Study to Investigate Safety, PK and Efficacy of the NaPi2b ADC TUB-040 in Patients With PROC or r/r Adenocarcinoma NSCLC
Набиране на участнициФаза 1/2
- Ohio State University, Columbus
A Study of Multiple Therapies in Biomarker-selected Participants With Resectable Stages IB-III Non-small Cell Lung Cancer (NSCLC)
Набиране на участнициФаза 2
- Ohio State University, Columbus
A Study of LY4050784 in Participants With Advanced or Metastatic Solid Tumors
Набиране на участнициФаза 1
- Ohio State University Hospital, Columbus
A Study of First-Line Olomorasib (LY3537982) and Pembrolizumab With or Without Chemotherapy in Patients With Advanced KRAS G12C-Mutant Non-small Cell Lung Cancer
Набиране на участнициФаза 3
- The James Cancer Hospital and Solove Research Institute at The Ohio State University Comprehensive Cancer -T, Columbus
A Study Evaluating the Efficacy and Safety of Divarasib and Pembrolizumab Versus Pembrolizumab and Pemetrexed and Carboplatin or Cisplatin in Participants With Previously Untreated, KRAS G12C-Mutated, Advanced or Metastatic Non-Squamous Non-Small Cell Lung Cancer
Набиране на участнициФаза 3
- Ohio State University, Columbus
A Study of Sofe-M in Participants With Selected Advanced Solid Tumors
Набиране на участнициФаза 1
- The Ohio State University (OSU) Wexner Medical Center, Columbus
Sotorasib in Combination With Trastuzumab Deruxtecan for the Treatment of Locally Advanced and Metastatic Non-small Cell Lung Cancer With a KRAS G12C Mutation
Набиране на участнициФаза 1/2
- Ohio State University Comprehensive Cancer Center, Columbus
Study to Evaluate Efficacy and Safety of Firmonertinib Compared With Investigator's Choice of EGFR Inhibitor as First-Line Treatment in Participants Who Have Locally Advanced or Metastatic NSCLC With EGFR P-Loop and Alpha C-Helix Compressing (PACC) Uncommon Mutations
Набиране на участнициФаза 3
- Ohio State University Hospitals, Columbus
KEYMAKER-U01 Umbrella Master Study: Studies of Investigational Agents With Either Pembrolizumab (MK-3475) Alone or With Pembrolizumab PLUS Chemotherapy in Participants With Non-small Cell Lung Cancer (NSCLC) (MK-3475-U01/KEYMAKER-U01)
Набиране на участнициНаблюдателно проучване
- Ohio State University Comprehensive Cancer Center ( Site 0015), Columbus
KEYMAKER-U01 Substudy 01A: Efficacy and Safety Study of Pembrolizumab (MK-3475) With or Without Chemotherapy When Used With Investigational Agents in Treatment-naïve Participants With Stage IV Non-small Cell Lung Cancer (NSCLC) (MK-3475-01A/KEYMAKER-U01A)
Набиране на участнициФаза 1/2
- The James Cancer Hospital and Solove Research Institute at The Ohio State University Comprehensive C ( Site 0015), Columbus
Testing Proton Craniospinal Radiation Therapy Versus the Usual Radiation Therapy for Leptomeningeal Metastasis, RADIATE-LM Trial
Набиране на участнициФаза 3
- Ohio State University Comprehensive Cancer Center, Columbus
Study to Assess GTAEXS617 in Participants With Advanced Solid Tumors
Набиране на участнициФаза 1/2
- The Ohio State University, Columbus
SMP-3124LP in Adults With Advanced Solid Tumors
Набиране на участнициФаза 1/2
- Ohio State University, Columbus
A Study of a Selective T Cell Receptor (TCR) Targeting, Bifunctional Antibody-fusion Molecule STAR0602 in Participants With Advanced Solid Tumors
Набиране на участнициФаза 1/2
- The Ohio State University Comprehensive Cancer Center, Columbus
Rinatabart Sesutecan (Rina-S, PRO1184, GEN1184) for Advanced Solid Tumors (GCT1184-01/ PRO1184-001)
Набиране на участнициФаза 1/2
- Ohio State University Comprehensive Cancer Center (OSUCCC)- The James Cancer Hospital and Solove Research Institute, Columbus
Clinical Trial Evaluating the Safety, Tolerability and Preliminary Efficacy of BNT116 Alone and in Combinations in Patients With Advanced Non-small Cell Lung Cancer
Набиране на участнициФаза 1
- Ohio State University, Columbus
Study of STK-012 Alone and With Other Treatments in Patients With Advanced Lung Cancer and Other Cancers
Набиране на участнициФаза 1/2
- The James Cancer Hospital and Solove Research Institute, Columbus
A Study to Evaluate the Safety, Tolerability, and Efficacy of Escalating Doses of BMS-986463 in Participants With Select Advanced Malignant Tumors.
Набиране на участнициФаза 1
- Local Institution - 0045, Columbus
Radiotherapy to Block Oligoprogression In Metastatic Non-Small-Cell Lung Cancer
Набиране на участнициФаза 3
- Ohio State University Comprehensive Cancer Center, Columbus
Evaluation of Geriatric Assessment and Management for Older Adults With Non-small Cell Lung Cancer Receiving Chemotherapy Radiation Therapy
Набиране на участнициЗдравите доброволци са добре дошли
- Ohio State University Comprehensive Cancer Center, Columbus
Autologous LN-145 in Patients With Metastatic Non-Small-Cell Lung Cancer
Набиране на участнициФаза 2
- Ohio State University Comprehensive Cancer Center, Columbus
A Study of LY4175408 in Participants With Advanced Cancer
Набиране на участнициФаза 1
- The Ohio State University (OSU) Wexner Medical Center, Columbus
Beating Lung Cancer in Ohio Protocol in Improving Survival in Patients With Stage IV Non-Small Cell Lung Cancer
Набиране на участници
- Ohio State University Comprehensive Cancer Center, Columbus
A Study to Evaluate the Safety and Efficacy of Mesothelin-Targeting Logic-gated CAR T, in Participants With Solid Tumors That Express MSLN and Have Lost HLA-A*02 Expression
Набиране на участнициФаза 1/2
- The Ohio State University Comprehensive Cancer Center, Columbus
KO-2806 Monotherapy and Combination Therapies in Advanced Solid Tumors
Набиране на участнициФаза 1
- Ohio State University, Columbus
Comparing Combinations of Targeted Drugs for Advanced Non-Small Cell Lung Cancer That Has EGFR and MET Gene Changes (A Lung-MAP Treatment Trial)
Набиране на участнициФаза 2
- Mount Carmel East Hospital, Columbus
- The Mark H Zangmeister Center, Columbus
- Mount Carmel Grove City Hospital, Grove City · на 7 мили
- и още 2
A Study of Repotrectinib (TPX-0005) in Patients With Advanced Solid Tumors Harboring ALK, ROS1, or NTRK1-3 Rearrangements
Набиране на участнициФаза 1/2
- The Ohio State University Wexner Medical Center, Columbus
Psilocybin-Assisted Therapy for the Treatment of Major Depressive Disorder in Patients With Non-Small Cell Lung Cancer
Набиране на участнициФаза 2
- Ohio State University Comprehensive Cancer Center, Columbus
Targeted Treatment for Advanced Non-Small Cell Lung Cancer That Has Increased Copies of the MET Gene (An Expanded Lung-MAP Treatment Trial)
Набиране на участнициФаза 2
- Ohio State University Comprehensive Cancer Center, Columbus
Adding the Immunotherapy Drug Cemiplimab to Usual Treatment for People With Advanced Non-Small Cell Lung Cancer Who Had Previous Treatment With Platinum Chemotherapy and Immunotherapy (An Expanded Lung-MAP Treatment Trial)
Набиране на участнициФаза 2/3
- Columbus Oncology and Hematology Associates Inc, Columbus
- Riverside Methodist Hospital, Columbus
- Grant Medical Center, Columbus
- и още 7
Adjuvant Pembrolizumab vs Observation Following Curative Resection for Stage I Non-small Cell Lung Cancer (NSCLC) With Primary Tumors Between 1-4 cm
Набиране на участнициФаза 2
- Ohio State University Comprehensive Cancer Center, Columbus
Targeted Treatment for Advanced Non-Small Cell Lung Cancer That Has a MET Exon 14 Skipping Gene Change (An Expanded Lung-MAP Treatment Trial)
Набиране на участнициФаза 2
- Ohio State University Comprehensive Cancer Center, Columbus
Safety and Tolerability of TNG456 Alone and in Combination With Abemaciclib in Patients With Solid Tumors With MTAP Loss
Набиране на участнициФаза 1/2
- Ohio State University Comprehensive Cancer Center, Columbus
Adagrasib + SRS for Patients With Metastatic KRAS G12C-mutated NSCLC With Untreated Brain Metastases
Набиране на участнициФаза 2
- Ohio State University Comprehensive Cancer Center, Columbus
Assessing Benefits and Harms of Cannabis/Cannabinoid Use Among Cancer Patients Treated in Community Oncology Clinics
Набиране на участнициНаблюдателно проучване
- Memorial Hospital, Marysville · на 27 мили
PBF-1129 and Nivolumab for the Treatment of Recurrent or Metastatic Non-Small Cell Lung Cancer
Набиране на участнициФаза 1
- Ohio State University Comprehensive Cancer Center, Columbus
GEMINI-NSCLC: NSCLC Biomarker Study
Набиране на участнициНаблюдателно проучване
- Ohio State University, Columbus
- OhioHealth Reseach Institute, Columbus
A Study of MT-4561 in Patients With Various Advanced Solid Tumors
Набиране на участнициФаза 1/2
- The James Cancer Hospital and Solove Research Institute at The Ohio State University Comprehensive Cancer Center, Columbus
SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and Registry
Набиране на участнициНаблюдателно проучване
- Massive Bio SYNERGY-AI site, Columbus
A Study to Evaluate the Safety and Efficacy of A2B395, an Allogeneic Logic-gated CAR T, in Participants With Solid Tumors That Express EGFR and Have Lost HLA-A*02 Expression
Набиране на участнициФаза 1/2
- The Ohio State University, Columbus
Проучвания за Рак на белия дроб с недребноклетъчен тип в други градове
- Houston, TX145 проучвания
- New York City, NY121 проучвания
- Arlington, VA104 проучвания
- Nashville, TN97 проучвания
- Boston, MA90 проучвания
- Los Angeles, CA87 проучвания
- St. Louis, MO73 проучвания
- Chicago, IL61 проучвания
- Baltimore, MD60 проучвания
- San Antonio, TX59 проучвания
- Washington, DC55 проучвания
- Seattle, WA53 проучвания
Други проучвания в Columbus
- Рак на гърдата40 проучвания
- Рак на яйчниците39 проучвания
- Рак (всички видове)38 проучвания
- Рак на белия дроб37 проучвания
- Остра миелоидна левкемия35 проучвания
- Хронична лимфоцитна левкемия28 проучвания
- Метастатичен рак27 проучвания
- Ендометриален рак25 проучвания
- Рак на простатата24 проучвания
- Множествен миелом24 проучвания
- Колоректален рак24 проучвания
- Меланом21 проучвания
От ClinicalTrials.gov, данни към 6.10.2026 г.. Всяко проучване има свои критерии за участие; екипът на проучването определя кой може да се включи.